|
Video: What is a Stock Split?
|
|
Esperion Therapeutics is a pharmaceutical company focused on developing and commercializing oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol (LDL-C). Co.'s first two products were approved by the U.S. Food and Drug Administration, European Medicines Agency, and Swiss Agency for Therapeutic Products. Bempedoic acid and the bempedoic acid / ezetimibe combination tablets are oral, once-daily, non-statin, LDL-C lowering medicines for patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia. According to our ESPR split history records, Esperion Therapeutics has had 0 splits. | |
|
Esperion Therapeutics (ESPR) has 0 splits in our ESPR split history database.
Looking at the ESPR split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Esperion Therapeutics shares, starting with a $10,000 purchase of ESPR, presented on a split-history-adjusted basis factoring in the complete ESPR split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/28/2024 |
|
Start price/share: |
$14.92 |
|
End price/share: |
$2.68 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-82.04% |
|
Average Annual Total Return: |
-15.78% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$1,796.21 |
|
Years: |
10.00 |
|
|
|
|
|